cardiovascular surgery condition
Conditions
Interventions
Unasyn-s 1.5g or sulbacillin 1.5g was administered intravenously within 15 min of the cardiovascular surgery. Venous blood samples were drawn every 30 min after the administration. Then, on days 3- af
Sponsors
Kagoshima University hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult patients who received ampicillin-sulbactam as antimicrobial prophylaxis during cardiovascular surgery
Exclusion criteria
Exclusion criteria: Neonate,infant,child,dialysis patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ampicillin (1 g)-sulbactam (0.5 g) was administered intravenously within 15 min of the cardiovascular surgery. Venous blood samples were drawn every 30 min after the administration. Then, on days 3- after initial administration venous dlood samples were drawn just before the next administration and after one hour i.v. infusion. Total concentrations of ampicillin and sulbactam in plasma were measured by high-performance liquid chromatography. Pharmacokinetic analyses of ampicillin and sulbactam were performed using the MULTI program. For each drug, total concentration-time data were fitted to a standard one-compartment model with zero-order input and first-order elimination. The pharmacokinetic parameters were volume of distribution (Vd, L) and total clearance (CL, L/h). Based on the means of the estimated Vd and CL values, the free concentration of ampicillin in plasma was predicted using the MULTI program, where the fraction of the plasma protein binding was assumed to be 20%. In the assessment of drug concentrations, values of 4 microg/mL were employed as a threshold (pharmacokinetic-pharmacodynamic target) for the free plasma concentrations of ampicillin, because the minimum inhibitory concentrations of ampicillin-sulbactam for 90% of the clinical isolates (MIC90) of methicillin-sensitive Staphylococcus aureus (MSSA) were estimated at 4 microg/mL in 2008 in Japan. This study aimed to determine the most appropriate timing for intraoperative dosing in order to maintain adequate concentrations throughout the operation. Also, we evaluate the pharmacokinetics of intravenously administered sulbactam to patients against acinetobacter baumannii infection. | — |
Countries
Japan
Contacts
Public ContactMATSUMOTO KAZUAKI
Graduate School of Medical and Dental Sciences Kagoshima University Clinical Pharmacy and Pharmacology
Outcome results
None listed